Who are ARRY-380, HER2 inhibitor; oral's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Herceptin, Herceptin, Trastuzumab and Hyaluronidase-oysk, PTH followed by dose dense AC of FEC, Herceptin Hylecta®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arry-380-her2-inhibitor-oral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ARRY-380, HER2 inhibitor; oral — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ARRY-380, HER2 inhibitor; oral (ARRY-380, HER2 inhibitor; oral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2 inhibitor. Area: Oncology.

phase 1 HER2 inhibitor HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ARRY-380, HER2 inhibitor; oral (ARRY-380, HER2 inhibitor; oral) — Seagen Inc.. HER2 inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARRY-380, HER2 inhibitor; oral TARGET	ARRY-380, HER2 inhibitor; oral	Seagen Inc.	phase 1	HER2 inhibitor	HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
Herceptin	Trastuzumab-Qyyp	Roche	marketed	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Trastuzumab and Hyaluronidase-oysk	Trastuzumab and Hyaluronidase-oysk	Adrienne G. Waks	marketed	Endoglycosidase [EPC]	HER2
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
Herceptin Hylecta®	Herceptin Hylecta®	Biocon Biologics UK PLC	marketed	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2 inhibitor class)

Centre Leon Berard · 1 drug in this class
Puma Biotechnology, Inc. · 1 drug in this class
Seagen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARRY-380, HER2 inhibitor; oral — Competitive Intelligence Brief. https://druglandscape.com/ci/arry-380-her2-inhibitor-oral. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab